The roles of maternal depression, serotonin reuptake inhibitor treatment, and concomitant benzodiazepine use on infant neurobehavioral functioning over the first postnatal month

American Journal of Psychiatry

Volumn 173, Issue 2, 2016, Pages 147-157

  Salisbury, Amy L ^a   O'Grady, Kevin E ^a   Battle, Cynthia L ^a   Wisner, Katherine L ^a   Anderson, George M ^a   Stroud, Laura R ^a   Miller Loncar, Cynthia L ^a   Young, Marion E ^a   Lester, Barry M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CLONAZEPAM; HYDROXYZINE; LORAZEPAM; MELATONIN; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; ZOLPIDEM TARTRATE; MOVO PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ADULT; ANXIETY DISORDER; AROUSAL; ARTICLE; AUDITORY STIMULATION; BEHAVIOR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG USE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; NEONATAL INTENSIVE CARE UNIT NETWORK NEUROBEHAVIORAL SCALE; NEWBORN; PATIENT ASSESSMENT; PERINATAL DEVELOPMENT; PERINATAL PERIOD; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PUERPERAL DEPRESSION; SCORING SYSTEM; SELF CONTROL; SYMPTOM; VISUAL STIMULATION; ANXIETY DISORDERS; CASE CONTROL STUDY; CHILD BEHAVIOR; CHILD DEVELOPMENT; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; HABITUATION; MALE; MUSCLE HYPOTONIA; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; ANXIETY DISORDERS; AROUSAL; BENZODIAZEPINES; CASE-CONTROL STUDIES; CHILD DEVELOPMENT; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; HABITUATION, PSYCHOPHYSIOLOGIC; HUMANS; INFANT BEHAVIOR; INFANT, NEWBORN; MALE; MUSCLE HYPOTONIA; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84957637646     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.14080989     Document Type: Article

References (49)

1. Gavin NI, Gaynes BN, Lohr KN, et al: Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005; 106:1071-1083
2. Grote NK, Bridge JA, Gavin AR, et al: A meta-analysis of depression during pregnancyand the risk of preterm birth, low birthweight, and intrauterine growth restriction. Arch Gen Psychiatry 2010; 67: 1012-1024
3. Salisbury AL, Lester BM, Seifer R, et al: Prenatal cocaine use and maternal depression: effects on infant neurobehavior. Neurotoxicol Teratol 2007; 29:331-340
4. Salisbury AL, Wisner KL, Pearlstein T, et al: Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment. Depress Anxiety 2011; 28:1008-1019
5. Conradt E, Lester BM, Appleton AA, et al: The roles of DNA methylation of NR3C1 and 11b-HSD2 and exposure to maternal mood disorder in utero on newborn neurobehavior. Epigenetics 2013; 8:1321-1329
6. Hay DF, Pawlby S, Waters CS, et al: Antepartum and postpartum exposure to maternal depression: different effects on different adolescent outcomes. J Child Psychol Psychiatry 2008; 49:1079-1088
7. Brennan PA, Hammen C, Andersen MJ, et al: Chronicity, severity, and timing of maternal depressive symptoms: relationships with child outcomes at age 5. Dev Psychol 2000; 36:759-766
8. Field T, DiegoM,Hernandez-ReifM:Depressedmothers' infants are less responsive to faces and voices. Infant Behav Dev 2009; 32: 239-244
9. Battle CL, Zlotnick C, Miller IW, et al: Clinical characteristics of perinatal psychiatric patients: a chart review study. J Nerv Ment Dis 2006; 194:369-377
10. Yonkers KA, Wisner KL, Stewart DE, et al: The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009; 31:403-413
11. Alwan S, Reefhuis J, Rasmussen SA, et al: Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 2011; 51:264-270
12. Chambers CD, Johnson KA, Dick LM, et al: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-1015
13. Moses-Kolko EL, Bogen D, Perel J, et al: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293: 2372-2383
14. Laine K, Heikkinen T, Ekblad U, et al: Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60:720-726
15. Rampono J, Simmer K, Ilett KF, et al: Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009; 42:95-100
16. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al: The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry 2013; 74: e309-e320
17. Maciag D, Simpson KL, Coppinger D, et al: Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006; 31:47-57
18. McAllister BB, Kiryanova V, Dyck RH: Behavioural outcomes of perinatal maternal fluoxetine treatment. Neuroscience 2012; 226: 356-366
19. Smith MV, Sung A, Shah B, et al: Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors. Early Hum Dev 2013; 89:81-86
20. Suri R, Hellemann G, Stowe ZN, et al: A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. J Clin Psychiatry 2011; 72:1002-1007
21. Zeskind PS, Stephens LE: Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113:368-375
22. Coyle MG, Salisbury AL, Lester BM, et al: Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction 2012; 107(suppl 1):63-73
23. Källén B, Reis M: Neonatal complications after maternal concomitant use ofSSRIand other central nervous system active drugs during the second or third trimester of pregnancy. J Clin Psychopharmacol 2012; 32:608-614
24. Oberlander TF, Misri S, Fitzgerald CE, et al: Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65:230-237
25. Gottfried AW: Measures of socioeconomic status in child development research: data and recommendations. Merrill-Palmer Q 1985; 31:85-92
26. First MB, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/NP). New York, Biometrics Research, New York State Psychiatric Institute, 2002
27. Rush AJ, Gullion CM, Basco MR, et al: The Inventory of Depressive Symptomatology (IDS): psychometric properties. PsycholMed1996; 26:477-486
28. TriveDi MH, Rush AJ, Ibrahim HM, et al: The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34:73-82
29. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
30. Sobell LC, Brown J, Leo GI, et al: The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend 1996; 42:49-54
31. Ingersoll KS, Farrell-Carnahan L, Cohen-Filipic J, et al: A pilot randomized clinical trial of two medication adherence and drug use interventions for HIV+ crack cocaine users. Drug Alcohol Depend 2011; 116:177-187
32. Nelson JC, Mazure CM, Bowers MB Jr, et al: A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48: 303-307
33. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. , Text Revision. Washington, DC, American Psychiatric Publishing, 2000
34. Lester BM, Tronick EZ: History and description of the Neonatal Intensive Care Unit Network Neurobehavioral Scale. Pediatrics 2004; 113:634-640
35. McCulloch CE, Searle SR, Neuhaus JM: Generalized, Linear, and Mixed Models. Hoboken, NJ, Wiley, 2008
36. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57:289-300
37. Warburton W, Hertzman C, Oberlander TF: A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 2010; 121: 471-479
38. Melchior JC, Svensmark O, Trolle D: Placental transfer of phenobarbitone in epileptic women, and elimination in newborns. Lancet 1967; 2:860-861
39. Liu J, Bann C, Lester B, et al: Neonatal neurobehavior predicts medical and behavioral outcome. Pediatrics 2010; 125:e90-e98
40. Sucharew H, Khoury JC, Xu Y, et al: NICU Network Neurobehavioral Scale profiles predict developmental outcomes in a lowrisk sample. Paediatr Perinat Epidemiol 2012; 26:344-352
41. Oberlander TF, Gingrich JA, Ansorge MS: Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther 2009; 86:672-677
42. Hanley GE, Brain U, Oberlander TF: Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressedmood and positive affect. EarlyHumDev 2013; 89: 519-524
43. Casper RC, Gilles AA, Fleisher BE, et al: Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology (Berl) 2011; 217:211-219
44. Santucci AK, Singer LT, Wisniewski SR, et al: Impact of prenatal exposure to serotonin reuptake inhibitors or maternal major depressive disorder on infant developmental outcomes. J Clin Psychiatry 2014; 75:1088-1095
45. Johnson KC, LaPrairie JL, Brennan PA, et al: Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry 2012; 69:787-794
46. Lam P, Hiscock H, Wake M: Outcomes of infant sleep problems: a longitudinal study of sleep, behavior, and maternal well-being. Pediatrics 2003; 111:e203-e207
47. Schmid G, Schreier A, Meyer R, et al: A prospective study on the persistence of infant crying, sleeping and feeding problems and preschool behaviour. Acta Paediatr 2010; 99:286-290
48. Anderson GM: Peripheral and central neurochemical effects of the selective serotonin reuptake inhibitors (SSRIs) in humans and nonhuman primates: assessing bioeffect and mechanisms of action. Int J Dev Neurosci 2004; 22:397-404
49. Palmsten K, Hernández-Díaz S: Can nonrandomized studies on the safety of antidepressants during pregnancy convincingly beat confounding, chance, and prior beliefs? Epidemiology 2012; 23:686-688